University of Alabama at Birmingham
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Alabama at Birmingham sits in the top decile of US sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count).
University of Alabama at Birmingham: 1,160 sponsored US clinical trials, 216 recruiting.
University of Alabama at Birmingham sponsors 1,160 registered US clinical trials on ClinicalTrials.gov, 216 of them currently recruiting, and 723 completed. 97 of these trials are in Phase 3-4 (later-stage) and 259 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
University of Alabama at Birmingham ranks in the top decile of sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
723 of 812 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,160 total, page 21 of 24
Effectiveness of a School-Based Hand Sanitizer Program on Reducing Asthma Exacerbations
NCT00528814
The Effect of Intravenous Lidocaine on Allodynia
NCT00659633
Sedation and Pain (The Effect of IV Sedation on Pain Perception)
NCT00853333
Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) Patients
NCT01112059
Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT
NCT00790062
Outcomes Associated With Progressive Balance And Gait Training Using The KineAssist® Robot
NCT02990650
Airway Management and Vascular Access Simulation
NCT00892671
Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies
NCT00937716
Continuous Labor Epidural Catheter for Tubal Ligation Study
NCT00898443
fMRI of Language Recovery Following Stroke in Adults
NCT00843427
Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study
NCT00756886
A Multi-Component Behavioral Nutrition Intervention for Homebound Elderly
NCT01197768
Hormonal Effects on Pain Perception
NCT00699595
Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
NCT00734344
The Effect of TRA-8 on Ovarian Cancer Tissue
NCT00711932
Reversal of Tobacco-Related Sinusitis
NCT00843869
Improving Quality of Osteoporosis Care Through Patient Storytelling
NCT01112098
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
NCT00714259
A Specialized Diet for the Unique Metabolic Characteristics of Peripubertal African American Girls
NCT00718874
Project inCharge: Increasing the Rate of Comprehensive Eye Care Utilization by Older African Americans Through Community-Based Eye Health Education Program
NCT00591110
A Multisite Trial of ACQUIREc Therapy
NCT00991692
Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
NCT00704691
Sensory Processing in Subjects With Painful Bladder Syndrome
NCT00903643
Assessment of Influence of Vitamin D on Insulin Secretion and Sensitivity in Obese Teenage Girls
NCT00851396
Comprehensive Exercise Training Program During Hospitalization for an Acute CF Exacerbation
NCT01759342
The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)
NCT00358306
The Effect of Intravenous Lidocaine on Normal Sensation and Pain in Healthy Volunteers
NCT00657358
Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation
NCT00582010
An Assessment of Bone Augmentation in Post-Extraction Sockets
NCT00641316
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
NCT00634270
Changes in Cancer-related Cytokines After Participation in a Physical Activity Behavior Change Intervention (CICK Study)
NCT00640666
Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT00655850
Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin
NCT00635050
Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia
NCT00622427
The Application of Performance Improvement Principles to the Patient Throughput Process in an Adult Outpatient Pain Treatment Clinic
NCT00888420
Complementary and Alternative Medicine for Urological Symptoms(CAMUS)
NCT00603304
Identification of Genetic Markers for Cardiopulmonary Diseases (Genotype)
NCT00616369
Acute Kidney Injury in Premature Infants
NCT00573079
UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer
NCT00570232
Investigation of Macular Pigment Augmentation on Dark Adaptation
NCT00478439
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
NCT00530868
Oral Health and People With Systemic Sclerosis
NCT01817361
BLYS and IFN in SLE
NCT00611611
Problem Solving Training and Low Vision Rehabilitation
NCT00545220
Can We Miss Pigmented Lesions in Psoriasis Patients?
NCT01053819
Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer
NCT00476216
Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT
NCT00478556
Effect of Macrolide Antibiotics on Airway Inflammation in People With Chronic Obstructive Pulmonary Disease (COPD)
NCT00549445
Collecting Information From Patients Enrolled in the Breast Specialized Program of Research Excellence
NCT01004562
The Effect of Bevacizumab (Avastin) on Pterygium
NCT00592176
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 129 |
| Phase 2 | 130 |
| Phase 3 | 25 |
| Phase 4 | 72 |
Therapeutic Areas
What is open in the University of Alabama at Birmingham pipeline
216 recruiting of 1,160 indexed (19% open); 723 completed (62%).
Phase mix: 97 late (III/IV) vs 259 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Alabama at Birmingham: open-pipeline peers nationwide
Peers matched on 1,160 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,160 trials (± recruiting share)
- NYU Langone Health · 1,164 trials · 17% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 19% open enrollment (± trial volume)
- University of Minnesota · 19% recruiting · 966 trials
- Mclean Hospital · 19% recruiting · 140 trials
- Children's Hospital Medical Center, Cincinnati · 19% recruiting · 571 trials
- Arkansas Children's Hospital Research Institute · 19% recruiting · 97 trials
Related
What to do with this University of Alabama at Birmingham page
1,160 registered trials is a research-attention snapshot, not an endorsement of University of Alabama at Birmingham or any single study.
- 216 of University of Alabama at Birmingham's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition University of Alabama at Birmingham studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Alabama at Birmingham pipeline card: 1,160 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.